introduction Treatment-predictive and prognostic factors are today of great importance in clinical practice for the choice of adjuvant therapy after breast cancer surgery. Several prognostic markers, like the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2), are also used as therapeutic targets. However, even though adjuvant therapy is directed against the targets present, some patients will still not respond to the treatment and experience a relapse in their disease. It is therefore important to find out more about prognostic and treatment-predictive markers in order to be better able to customise treatment according to the needs of individual patients. One interesting new possible prognostic and/or treatment-predictive factor is amplified in breast cancer 1 (AIB1), also known as steroid receptor coactivator-3, nuclear coactivator-3, p300/CBP interacting protein, receptor associated coactivator-3, activator of thyroid hormone and retinoid receptor, and thyroid hormone receptor activating molecule-1.
The AIB1 gene was discovered upon microdissection of region 20q [1] , a region which is often amplified in breast cancer [2, 3] . It belongs to the steroid receptor coactivator family and interacts with the ER in a ligand-dependent manner to enhance transcription [4] [5] [6] [7] . Previous studies have shown that AIB1 has oncogene potential and indicate an important role in breast cancer development. Overexpression of AIB1 has been found in 30%-60% of human breast tumours and gene amplification in 5%-10% [1, [4] [5] [6] . AIB1 is essential for estrogen-dependent cell growth in the breast cancer cell line MCF-7 [8] , and in mice, overexpression of AIB1 induces mammary tumorigenesis, while absence of AIB1 protects against this [9] [10] [11] .
Although preclinical trials indicate an important role of AIB1 in breast cancer development and progression, results regarding AIB1 as a prognostic and a treatment-predictive factor in clinical breast cancer cohorts have been ambiguous. However, as far as we know, no previous study has been carried out in a controlled randomised trial. High AIB1 has been shown to correlate with factors indicating a more aggressive phenotype (high S-phase fraction, HER2 positivity, DNA nondiploidy, and high tumour grade) [12] [13] [14] [15] . Regarding AIB1's correlation with ER and progesterone receptor (PgR), results are conflicting [4, 6, [12] [13] [14] [15] [16] .
In a previous study by Osborne et al. [14] , overexpression of AIB1 was found to be a positive prognostic factor in untreated patients, though it was associated with a lower disease-free survival (DFS) in patients receiving adjuvant tamoxifen treatment. Harigopal et al. [17] on the other hand found high AIB1 to correspond with a worse patient outcome in an unselected cohort of patients. In tamoxifen-treated patients, Kirkegard et al. [13] did not find a correlation between AIB1 and DFS, while Dihge et al. and Meyers et al. showed a correlation between high AIB1 and recurrences during tamoxifen treatment [12, 18] . Different results were obtained by Iwase et al. [16] , who found patients with high AIB1 to respond well to hormonal treatment.
In summary, AIB1's role as a prognostic and treatmentpredictive factor is not fully understood. In this study, we want to further address this issue by using a randomised controlled trial of tamoxifen versus no tamoxifen in premenopausal women with stage II breast cancer. Patients were included and randomised irrespectively of hormonal receptor status. Hence, the material is unique and allows an excellent opportunity for studying prognostic and treatment-predictive factors in premenopausal primary breast cancer.
materials and methods

study design
From 1986 to 1991, 564 premenopausal breast cancer patients were enrolled and randomly assigned to 2 years of adjuvant tamoxifen treatment versus no tamoxifen treatment. Characteristics of this trial have been described in detail before [19] . Briefly, all patients had unifocal, stage II breast cancer and were entered into a randomised study independent of ER and PgR status. Stratification for tumour size or lymph node status was not included in the protocol. Patients with breast-conserving surgery or node-positive disease received radiotherapy according to the clinical standards. Less than 2% received additional adjuvant treatment. Median duration of follow-up for patients without a breast cancer event was 14 years. The trial was planned to include at least 500 patients, aiming at a 15% difference in outcome between the two arms, with 90% power and an alpha level of 5%. Randomisation was carried out by the Regional Oncological Centres. A central secretariat was called, in which a closed envelope with a prerandomised allocation was selected. Patient identity, date, department, and allocated treatment were documented by the secretariat, and also on case report forms by each institution. The study was not blinded, thus the control group did not receive placebo instead of tamoxifen. Oral informed consent was registered for all patients and the study was approved by the ethical committees at the Universities of Lund and Linköping. The study is registered as 'SBII:2' in accordance with the criteria outlined by the International Committee of Medical Journal Editors, at the Regional Oncological Centres in Lund and Linköping respectively. Study design and patient flow are described in more detail in Figure 1 .
tissue microarray and immunohistochemical staining
Paraffin blocks from the primary tumours were available for 500 of the 564 patients included in the study. From representative areas of the invasive breast cancers, tissue core biopsies were punched out and mounted into the recipient block using a tissue array machine according to the manufacturer's instructions (Beecher Instruments, Sun Prairie, WI). A mouse monoclonal IgG antibody was used as primary antibody for AIB1 detection (BD Bioscience, San José, CA). This antibody has been used in several previous clinical trials [5, 12, 13] , and its specificity has been confirmed by western blot, northern blot, and in situ hybridisation [5, 13, 20] . Immunohistochemical staining was carried out by an automatic immunostainer (TechMateä500 Plus, DAKO, Glostrup, Denmark), DAKO Envisionä, as described in a previous study published from our group [12] .
AIB1 staining evaluation
Immunohistochemical staining of AIB1 was examined by light microscope by two independent viewers blinded for clinical and tumour characteristic data (SA and KL). All divergent results were re-examined by a pathologist (DG). Cases with lost TMA cores, with only cancer in situ or with <10 cancer cells, were excluded, leaving 349 cases for evaluation. Staining was mainly seen in the cell nuclei. Each sample was given semi-quantitative scores from 0-3 for both the percentage of stained nuclei (proportion score) and the intensity of positive cells (intensity score), as in a previous study published from our group [12] . Proportion score 0 represents no stained cell nuclei, score 1, 1%-10%; score 2, 11%-50%; and score 3, 51%-100% stained tumour cell nuclei. Staining intensity 0 represents negative staining and 3 represents intense staining. Proportion and intensity scores were then added to give a total score ranging from 0 to 6. In case of discrepant staining results between the two cores from the same patient, the core with the highest score was used in the further analyses.
In accordance with a previous study by our group, a total score of ‡5 was considered as high AIB1 and a total score <5 as low AIB1 [12] .
analysis of other tumour characteristics ER and PgR were analysed by immunohistochemistry (IHC) as previously described [21] . In line with a clinically established cut-off used for hormone receptor assessment, tumours with >10% stained nuclei were considered positive. Nottingham histological grade (NHG) was evaluated following a written protocol [19] . NHG 1-2 was considered as low and 3 as high. HER2 was measured both by IHC and by FISH [21] . All patients with Of the 564 women included in the study, AIB1 scores were obtained from 349. When comparing these 349 with the 215 women without AIB1 scores, analysis showed no significant difference regarding age, lymph node status, tumour size, NHG, HER2, ER, and PgR (data not shown).
Characteristics of the treatment groups were similar, with the exceptions of a higher proportion of larger tumours in the Table 1 . Patient and tumour characteristics in relation to treatment arm
Variable
Present study (N = 349) Original study (N = 564) All patients (N = 349) (%) group which received tamoxifen therapy and a higher proportion of HER2-positive patients in the control group (Table 1) . AIB1 antibody binding in the nucleus of breast cancer cells was found in 347 patients (99%). Fifty-six per cent of the samples were classified as high AIB1.
correlation between AIB1 and other prognostic and treatment-predictive factors
High expression of AIB1 was found to correlate with ER negativity (P = 0.02) and PgR negativity (P = 0.001). There was also an association to HER2 positivity (P = 0.03), high NHG (P < 0.001), and presence of lymph node metastases (P = 0.02). No significant association to age or tumour size was seen ( Table 2 ).
AIB1 as a prognostic factor for RFS and OS
AIB1 as a prognostic factor was investigated in the control group that was not allocated to adjuvant treatment. High AIB1 was significantly associated with a lower RFS [HR 1.6, 95%
confidence interval (CI) 1.1-2.5, P = 0.02] and OS (HR 1.7, 95% CI 1.1-2.7, P = 0.02) (Figure 2 ). In multivariate analysis (adjusted for age, tumour size, HER2, NHG, lymph node status, ER, and PgR), statistical significance remained for RFS (HR 1.7, 95% CI 1.0-2.7, P = 0.04) but not for OS (HR 1.5, 95% CI 0.9-2.6, P = 0.1) ( Table 3 ). Lymph node status was the strongest independent predictor of RFS. In subgroup analysis, the prognostic effect of AIB1 was seen only in patients with ER-positive tumours (RFS: HR 1.8, 95% CI 1.1-3.0, P = 0.02 and OS: HR 1.9, 95% CI 1.1-3.3, P = 0.01), but not in ER-negative tumours (RFS: HR 1.5, 95% CI 0.6-4.1, P = 0.4 and OS: HR 1.2, 95% CI 0.5-3.1, P = 0.6). Similar results were seen when stratifying for PgR status. However, these differences in AIB1 effects between ER-positive and ERnegative patients were not significant (Cox models with an interaction term, data not shown).
AIB1 as a predictive factor for response to tamoxifen treatment
In ER-positive patients with low AIB1, there was no difference in RFS (HR 0.9, 95% CI 0.5-1.6, P = 0.8) or OS (HR 1.0, 95% CI 0.5-1.8, P = 1.0) in relation to tamoxifen treatment, indicating no treatment effect in this group. However, in ERpositive patients with high AIB1 tamoxifen treatment increased both RFS (HR 0.4, 95% CI 0.2-0.7, P = 0.002) and OS (HR 0.4, 95% CI 0.2-0.8, P = 0.003) significantly (Figure 3 ). No effect of tamoxifen was seen in the ER-negative group, with either high or low AIB1 (data not shown).
When, in ER-positive patients, using a Cox model with AIB1 (high versus low) and treatment (tamoxifen versus no tamoxifen) and an interaction term, the interaction was borderline significant for both RFS (HR 0.5, 95% CI 0.2-1.0, P = 0.05) and OS (HR 0.4, 95% CI 0.2-1.0, P = 0.05). When adjusting for other prognostic markers (age, tumour size, NHG, HER2, and lymph node status), the interaction was statistically significant, indicating that AIB1 could be a predictive marker of response to tamoxifen treatment (Table 4) . discussion This is the first time, as far as we know, that expression of AIB1 has been studied in a controlled randomised trial including only premenopausal patients, giving us an excellent opportunity to investigate AIB1 as both a prognostic and treatment-predictive marker. In ER-positive patients not allocated to tamoxifen, we found high AIB1 to be significantly associated with both reduced RFS and OS. However, ERpositive patients with high AIB1 responded very well to tamoxifen treatment, increasing both RFS and OS to the same levels as in systemically untreated patients with low AIB1. This indicates AIB1 to be a negative prognostic, but a positive tamoxifen treatment-predictive factor. As in previous studies, we show high expression of AIB1 to be associated with other factors indicating a worse prognosis (HER2 positivity and high NHG). High AIB1 was also associated with presence of lymph node metastases. Regarding AIB1's correlation to hormonal receptors, results from previous studies have been contradictory. In this cohort of patients, we found a significant association to the absence of ER and PgR. In line with our results, Harigopal et al. [17] found AIB1 to be a negative prognostic factor, associated with a worse patient outcome. This also correlates well with what has been seen in other tumour types and AIB1's association to negative prognostic markers [12-15, 22, 23] . However, there have also been other studies suggesting AIB1 to be a positive prognostic marker or not to be associated with prognosis at all; although none of these studies were done in a randomised trial [14, 24] .
Our results indicate that AIB1 to be a predictive factor of response to tamoxifen treatment. In ER-positive patients with high AIB1, tamoxifen increased RFS and OS to the same levels as in systemically untreated patients with low AIB1. Although ER-positive patients with low AIB1 had a better RFS and OS without treatment, this was not further improved by tamoxifen. In fact, in this group, no difference between tamoxifen and no tamoxifen could be seen. Consistent with our results, previous studies by Kirkegaard et al. and Dihge et al. showed no difference in overall RFS in tamoxifen-treated patients with a longer follow-up ( ‡5 years), although Dighe et al. did find a correlation to early recurrences [12, 13] . In a recent study, it was found that AIB1 was a negative prognostic factor only in ER-negative patients [17] . Unfortunately, complete treatment information is unavailable in this study. However, if many of the ER-positive patients did receive tamoxifen, these results might be explained by what we see in our study, i.e. patients with high AIB1 respond very well to tamoxifen, reducing differences in RFS and OS between patients with high versus low AIB1. On the other hand, Osborne et al. [14] found high AIB1 to be a negative prognostic factor in the tamoxifentreated group. Underlying mechanisms for the reported contradictory results may be explained by different study design (randomised versus unselected cohort) and differences in methodology and cut-off. Although both studies estimate protein levels of AIB1, we use IHC while Osborne et al. [14] use western blot. Apart from full-length AIB1, the antibody used might detect also the 30 kDa lighter splice variant AIB1-D3 [5, 25] . If this, more active, isoform is included when analysing IHC, but not during western blot, this could affect the result.
Since no consensus for the choice of cut-off value for AIB1 could be found in the literature, we analysed AIB1 scores in accordance with a previous study by our group [12] . We found 56% of the tumours to express high levels of AIB1. This is well consistent with several previous studies, where 40%-60% of the breast cancers have shown overexpression of AIB1 [4, 5, 12, 17] . However, Bouras et al. [15] found overexpression of AIB1 messenger RNA in only 31% of primary breast cancers, and in a study by Iwase et al. [16] , only 16% of the patients showed nuclear staining of AIB1. Reasons for these discrepancies are unclear, but might be explained by differences in methodology and patient selection. In the studies by Osborne et al. and Kirkegaard et al., they defined high AIB1 as tumours in the top quartile of AIB1 expression [13, 14] . When doing subgroup analysis of the 56% AIB1-positive patients in our study (the highest 18% compared with the remaining 38%), we found no significant difference between these groups (data not shown).
Another important aspect is that the presented study only includes premenopausal women, while in the study of Osborne et al., 85% of the patients were at least 50 years old, indicating a large majority of postmenopausal women. A possible hypothesis is that effects of AIB1 can be modified depending on the presence of estrogen. Previous studies have shown that, apart from acting as a coactivator to ER, AIB1 can interact with other transcription factors and signalling pathways like E2F1, nuclear factor kappa-light-chain-enhancer of activated B cells, insulin-like growth factor 1/AKT, C/EBPb, and HER2/neu/ Mitogen-activated protein kinase [14, [26] [27] [28] [29] [30] [31] , leading to hormone-independent cell proliferation. A possible theory is that AIB1 in the presence of estrogen acts mainly as a coactivator to the ER and that this effect is inhibited by tamoxifen, but in the postmenopausal setting, with low estrogen levels, other pathways may be more important. Further studies should address this issue by studying AIB1's role in a controlled randomised trial of tamoxifen treatment including postmenopausal women. Previous studies have indicated an association between HER2 and AIB1. In patients receiving tamoxifen, Osborne et al. and Kirkegaard et al. found the worst outcome among patients with both high AIB1 and HER2 positivity [13, 14] . Similar results have also been seen in another study [12] . Flemming et al. [32] on the other hand found no correlation between AIB1 and recurrences on endocrine treatment in HER2-positive patients. In this patient material, we found HER2 positivity in itself to be a negative prognostic factor. High versus low AIB1 did not significantly change the effects of HER2, either in the whole patient material or in subgroups in relation to tamoxifen treatment and ER. However, our study, as well as most other studies, contains few patients that are both AIB1 positive and HER2 positive. Therefore, no real conclusions regarding the association between HER2 and AIB1 can be drawn from this study due to lack of statistical power. Furthermore, HER2-positive patients were unequally distributed between the tamoxifen-treated arm and the control arm.
In conclusion, this is, to our knowledge, the first time AIB1 as a prognostic and tamoxifen treatment-predictive factor has been explored in a controlled randomised trial. In contrast to earlier clinical trials, the study includes only premenopausal women, making direct comparison to previous publications difficult. We found AIB1 to be a negative prognostic factor for RFS and OS. We also found that ER-positive patients with high AIB1 responded significantly to tamoxifen treatment, while no tamoxifen effect was seen in ER-positive patients with low AIB1. The implication of this is that high AIB1 is an independent predictive factor of improved response to tamoxifen in premenopausal women and not tamoxifen resistance as has previously been discussed in unselected cohorts. 
